H-Index
79
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
16%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
AmJCaseRep

Annals
ISI-Home

eISSN: 1643-3750

Successful treatment of immune thrombocytopenic purpura (ITP) with the thrombopoietin-mimetic Romiplostim

John Meletis, Aikaterini Katsandris, Sophia D. Raptis, Marina Mantzourani

Med Sci Monit 2010; 16(8): CS100-102

ID: 881091

Available online: 2010-08-01

Published: 2010-08-01


#881091

Background:    Romiplostim is a second-generation thrombopoietic receptor agonist that exerts its therapeutic effect by stimulating megakaryopoiesis.
    Case Report:    We report a patient with immune thrombocytopenic purpura refractory to other therapies including splenectomy, which was successfully managed with romiplostim. More specifically, the patient’s platelet count showed a 3-fold increase within 7 days following the first dose of romiplostim (from 33×109/l to 96×109/l).
    Conclusions:    Romiplostin is a new trombopoietin peptide mimetic drug, which seems to be very effective for the management of refractory chronic ITP in adults.

Keywords: Thrombopoietin - therapeutic use, Recombinant Fusion Proteins - therapeutic use, Receptors, Fc - therapeutic use, Purpura, Thrombocytopenic, Idiopathic - drug therapy, Adult



Back